Just days after sources said the European Commission was preparing to issues fines against generic drug makers for anticompetitive practices, reports say authorities in the US are also revamping their efforts against unfair tactics in the pharmaceutical industry.
According to reports, the Federal Trade Commission launched new investigations into pay-for-delay agreements …read more
Source: Global Competition Law Blogs